Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure
© 2022 by the American Diabetes Association..
OBJECTIVE: To examine the association of race/ethnicity and socioeconomic deprivation with initiation of guideline-recommended diabetes medications with cardiovascular benefit (glucagon-like peptide 1 receptor agonists [GLP1-RA] and sodium-glucose cotransporter 2 inhibitors [SGLT2i]) among older adults with type 2 diabetes (T2D) and either incident atherosclerotic cardiovascular disease (ASCVD) or congestive heart failure (CHF).
RESEARCH DESIGN AND METHODS: Using Medicare data (2016-2019), we identified 4,057,725 individuals age >65 years with T2D and either incident ASCVD or CHF. We estimated incidence rates and hazard ratios (HR) of GLP1-RA or SGLT2i initiation within 180 days by race/ethnicity and zip code-level Social Deprivation Index (SDI) using adjusted Cox proportional hazards models.
RESULTS: Incidence rates of GLP1-RA or SGLT2i initiation increased over time but remained low (<0.6 initiations per 100 person-months) in all years studied. Medication initiation was less common among those of Black or other race/ethnicity (HR 0.81 [95% CI 0.79-0.84] and HR 0.84 [95% CI 0.75-0.95], respectively) and decreased with increasing SDI (HR 0.96 [95% CI 0.96-0.97]). Initiation was higher in ASCVD than CHF (0.35 vs. 0.135 initiations per 100 person-months). Moderate (e.g., nephropathy, nonalcoholic fatty liver disease) but not severe (e.g., advanced chronic kidney disease, cirrhosis) comorbidities were associated with higher probability of medication initiation.
CONCLUSIONS: Among older adults with T2D and either ASCVD or CHF, initiation of GLP1-RA or SGLT2i was low, suggesting a substantial deficit in delivery of guideline-recommended care or treatment barriers. Individuals of Black and other race/ethnicity and those with higher area-level socioeconomic deprivation were less likely to initiate these medications.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
---|---|
Enthalten in: |
Diabetes care - 46(2023), 1 vom: 01. Jan., Seite 65-74 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cromer, Sara J [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 26.12.2022 Date Revised 02.01.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.2337/dc22-0383 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM348968787 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM348968787 | ||
003 | DE-627 | ||
005 | 20240108140633.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2337/dc22-0383 |2 doi | |
028 | 5 | 2 | |a pubmed24n1246.xml |
035 | |a (DE-627)NLM348968787 | ||
035 | |a (NLM)36383481 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Cromer, Sara J |e verfasserin |4 aut | |
245 | 1 | 0 | |a Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.12.2022 | ||
500 | |a Date Revised 02.01.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022 by the American Diabetes Association. | ||
520 | |a OBJECTIVE: To examine the association of race/ethnicity and socioeconomic deprivation with initiation of guideline-recommended diabetes medications with cardiovascular benefit (glucagon-like peptide 1 receptor agonists [GLP1-RA] and sodium-glucose cotransporter 2 inhibitors [SGLT2i]) among older adults with type 2 diabetes (T2D) and either incident atherosclerotic cardiovascular disease (ASCVD) or congestive heart failure (CHF) | ||
520 | |a RESEARCH DESIGN AND METHODS: Using Medicare data (2016-2019), we identified 4,057,725 individuals age >65 years with T2D and either incident ASCVD or CHF. We estimated incidence rates and hazard ratios (HR) of GLP1-RA or SGLT2i initiation within 180 days by race/ethnicity and zip code-level Social Deprivation Index (SDI) using adjusted Cox proportional hazards models | ||
520 | |a RESULTS: Incidence rates of GLP1-RA or SGLT2i initiation increased over time but remained low (<0.6 initiations per 100 person-months) in all years studied. Medication initiation was less common among those of Black or other race/ethnicity (HR 0.81 [95% CI 0.79-0.84] and HR 0.84 [95% CI 0.75-0.95], respectively) and decreased with increasing SDI (HR 0.96 [95% CI 0.96-0.97]). Initiation was higher in ASCVD than CHF (0.35 vs. 0.135 initiations per 100 person-months). Moderate (e.g., nephropathy, nonalcoholic fatty liver disease) but not severe (e.g., advanced chronic kidney disease, cirrhosis) comorbidities were associated with higher probability of medication initiation | ||
520 | |a CONCLUSIONS: Among older adults with T2D and either ASCVD or CHF, initiation of GLP1-RA or SGLT2i was low, suggesting a substantial deficit in delivery of guideline-recommended care or treatment barriers. Individuals of Black and other race/ethnicity and those with higher area-level socioeconomic deprivation were less likely to initiate these medications | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
650 | 7 | |a 89750-14-1 |2 NLM | |
650 | 7 | |a Glucagon-Like Peptide-1 Receptor |2 NLM | |
650 | 7 | |a Hypoglycemic Agents |2 NLM | |
700 | 1 | |a Lauffenburger, Julie C |e verfasserin |4 aut | |
700 | 1 | |a Levin, Raisa |e verfasserin |4 aut | |
700 | 1 | |a Patorno, Elisabetta |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Diabetes care |d 1979 |g 46(2023), 1 vom: 01. Jan., Seite 65-74 |w (DE-627)NLM00042983X |x 1935-5548 |7 nnns |
773 | 1 | 8 | |g volume:46 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:65-74 |
856 | 4 | 0 | |u http://dx.doi.org/10.2337/dc22-0383 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 46 |j 2023 |e 1 |b 01 |c 01 |h 65-74 |